Table 5 Toxicity at recommended Phase II dose (dose level 2, n=20 patients)

From: A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

 

All grades

Grade 3–4

 

n (%)

n (%)

Haematological

 Thrombocytopaenia

11 (55)

7 (35)

 Leucopaenia

6 (30)

6 (30)

 Neutropaenia

6 (30)

6 (30)

 Anaemia

5 (25)

2 (10)

Nonhaematological

 Fatigue

10 (50)

— (−)

 Nausea

7 (35)

1 (5)

 Constipation

6 (30)

1 (5)

 Headache

5 (25)

— (−)

 Haemorrhage

5 (25)

4 (20)

 Pain

2 (10)

— (−)

 Dyspnoea

2 (10)

1 (5)

 Sepsis

2 (10)

2 (10)

 Diarrhoea

1 (5)

— (−)

 Pulmonary fibrosis

1 (5)

1 (5)

Back to article page